Stocks · News reference
BridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BridgeBio Says Acoramidis Associated With 34% Lower Risk Of Clinical Worsening vs. Tafamidis In Real-World Study
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.